Saleh Velez Faddi G, Ortiz Garcia Jorge G
Department of Neurology, University of Chicago, Chicago, IL, United States of America.
Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America.
eNeurologicalSci. 2021 Apr 15;23:100341. doi: 10.1016/j.ensci.2021.100341. eCollection 2021 Jun.
Pulmonary embolism (PE) and acute ischemic stroke (AIS) are common disorders with high morbidity and mortality, rarely presenting simultaneously. There is a paucity of data regarding the management of this uncommon presentation. The treatment of these two entities is complex in the acute phase due to the concomitant need for thrombolysis in AIS and anticoagulation for PE.
We retrospectively reviewed confirmed ischemic stroke cases to identify patients presented with simultaneous PE from June 2018 to May 2019. Additionally, a literature review was performed. Two reviewers assessed the manuscripts' quality, and relevant data regarding clinical course and management was extracted.
We reviewed 439 patient charts, identifying two cases of concomitant AIS and PE. Additionally, twelve articles (n = 15 subjects) fulfilled our literature review criteria for a total of 17 cases, including ours. Intravenous anticoagulation (70.5%) was the most frequent intervention targeting both disorders. Therapies such as intravenous thrombolysis (23.53% (n = 4)) and mechanical thrombectomy (23.53% (n = 4)) were specific in AIS. Catheter-directed thrombolysis (5.88%) was used for PE. Clinical outcomes were favorable (asymptomatic or mild disable symptoms) in 47.05% (N = 8) of patients, while 41.17% had poor outcomes (severe disable symptoms or death).
AIS and PE stand for a challenge when they present simultaneously. The evaluation of risks and benefits of therapies such as intravenous thrombolysis, mechanical thrombectomy, and catheter-directed-thrombolysis in the clinical context is essential. According to our review, the ischemic stroke burden guides systemic anticoagulation decisions over interventional procedures when the hemodynamic status remains unaffected.
肺栓塞(PE)和急性缺血性卒中(AIS)是常见疾病,发病率和死亡率高,很少同时出现。关于这种不常见表现的管理数据匮乏。由于AIS急性期需要溶栓以及PE需要抗凝,这两种疾病在急性期的治疗很复杂。
我们回顾性分析确诊的缺血性卒中病例,以确定2018年6月至2019年5月期间同时发生PE的患者。此外,进行了文献综述。两名审阅者评估手稿质量,并提取有关临床病程和管理的相关数据。
我们审查了439份患者病历,确定了2例同时发生AIS和PE的病例。此外,12篇文章(n = 15名受试者)符合我们的文献综述标准,总共17例,包括我们的病例。静脉抗凝(70.5%)是针对这两种疾病最常用的干预措施。静脉溶栓(23.53%(n = 4))和机械取栓(23.53%(n = 4))等治疗方法是AIS特有的。导管定向溶栓(5.88%)用于PE。47.05%(N = 8)的患者临床结局良好(无症状或轻度残疾症状),而41.17%的患者结局不佳(严重残疾症状或死亡)。
AIS和PE同时出现时是一个挑战。在临床背景下评估静脉溶栓、机械取栓和导管定向溶栓等治疗方法的风险和益处至关重要。根据我们的综述,当血流动力学状态未受影响时,缺血性卒中的严重程度指导全身抗凝决策而非介入治疗。